# Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

> **NCT05355077** · PHASE1 · WITHDRAWN · sponsor: **Shanghai Vinnerna Biosciences Co., Ltd.**

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** JT001 200mg Bid
- **DRUG:** JT001 400mg Bid
- **DRUG:** JT001 600mg Bid

## Key facts

- **NCT ID:** NCT05355077
- **Lead sponsor:** Shanghai Vinnerna Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05-02
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-10-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Development strategy adjustment
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05355077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05355077, "Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05355077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*